Share-based Payment Arrangement, Expense of IO Biotech, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
IO Biotech, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • IO Biotech, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,476,000, a 12% decline year-over-year.
  • IO Biotech, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $6,286,000, a 2.5% decline year-over-year.
  • IO Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,526,000, a 19% decline from 2023.
  • IO Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8,059,000, a 14% increase from 2022.
  • IO Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,040,000, a 293% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

IO Biotech, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,286,000 $1,476,000 -$207,000 -12% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $6,493,000 $1,607,000 -$35,000 -2.1% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $6,528,000 $1,569,000 +$2,000 +0.13% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $6,526,000 $1,634,000 +$76,000 +4.9% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $6,450,000 $1,683,000 -$1,306,000 -44% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $7,756,000 $1,642,000 +$18,000 +1.1% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $7,738,000 $1,567,000 -$321,000 -17% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $8,059,000 $1,558,000 -$103,000 -6.2% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $8,162,000 $2,989,000 +$588,000 +24% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $7,574,000 $1,624,000 +$266,000 +20% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $7,308,000 $1,888,000 +$268,000 +17% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $7,040,000 $1,661,000 +$362,000 +28% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
Q3 2022 $6,678,000 $2,401,000 +$1,918,000 +397% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $4,760,000 $1,358,000 +$1,353,000 +27060% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $3,407,000 $1,620,000 +$1,616,000 +40400% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $1,791,000 $1,299,000 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q3 2021 $483,000 +$467,000 +2919% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $5,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $4,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 $16,000 01 Jul 2020 30 Sep 2020 10-Q 17 Dec 2021 2021 Q3

IO Biotech, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,526,000 -$1,533,000 -19% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $8,059,000 +$1,019,000 +14% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $7,040,000 +$5,249,000 +293% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 $1,791,000 +$1,727,000 +2698% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
2020 $64,000 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.